Update on chronic viral hepatitis

Postgraduate Medical Journal

Volumn 77, Issue 910, 2001, Pages 498-505

  Walsh, K ^a   Alexander, G J M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Hepatitis

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ALOPECIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC HEPATITIS; DEPRESSION; DISEASE COURSE; FLU LIKE SYNDROME; HEADACHE; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HEPATITIS G VIRUS; HUMAN; IRRITABILITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MYALGIA; RASH; SLEEP DISORDER; TORQUE TENO VIRUS; VIRUS HEPATITIS; VIRUS TRANSMISSION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS, CHRONIC; HEPATITIS, VIRAL, HUMAN; HUMANS; IMMUNOBLOTTING; LIVER TRANSPLANTATION; MALE; POLYMERASE CHAIN REACTION;

EID: 0034888990     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.77.910.498     Document Type: Article

References (101)

1. The epidemiology of viral hepatitis in the United States
2. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994
3. Molecular virology and pathogenesis of hepatitis B
4. Hepatitis B: Virology, epidemiology, disease, and prevention, and an overview of viral hepatitis
5. Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state
6. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men
7. Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B
8. The serologic course of hepatitis B surface antigen and e antigen and the development of primary hepatocellular carcinoma in asymptomatic carriers of hepatitis B virus
9. Hepatitis B surface antigen disappearance and hepatitis B surface antigen subtype: A prospective, long-term, follow-up study of Japanese residents of Okinawa, Japan with chronic hepatitis b virus infection
10. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis
11. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period
12. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients
13. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection
14. A randomized controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B
15. Long-term remission of chronic hepatitis B after alpha-interferon therapy
16. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection
17. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis
18. A one-year trial of lamivudine for chronic hepatitis B
19. A phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection
20. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications
21. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
22. Liver transplantation in European patients with the hepatitis B surface antigen
23. Lamivudine prophylaxis against reinfection in liver transplantation foe hepatitis B cirrhosis
24. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
25. Risk factors for lack of detectable antibody following hepatitis B vaccinations of Minnesota health care workers
26. Hepatitis B vaccine in medical staff of haemodialysis units: Efficacy and subtype cross-protection
27. The prevention of hepatitis B with vaccine: Report of the Centers for Disease Control Multi-Center Efficacy trial among homosexual men
28. Yeast-recombinant hepatitis B vaccine: Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission
29. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - Results of a 10-year study
30. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA
31. The emerging pattern of post-transfusion hepatitis
32. Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis-genome
33. A proposed system for the nomenclature of hepatitis C viral genotypes
34. Hepatitis C virus and liver diseases
35. Epidemiology of hepatitis C in the East
36. EASL International Consensus Conference on Hepatitis C
37. Hepatitis C viraemia in United Kingdom blood donors. A multicentre study
38. Transmission of hepatitis C virus by organ transplantation in the United Kingdom
39. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
40. Hepatitis C virus infection in medical personnel after needlestick accident
41. Hepatitis C virus infection in healthcare workers: Risk of exposure and infection
42. A prospective study of hepatitis C virus infection after needlestick accidents
43. Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug abusers
44. Non-A, non-B hepatitis associated with chronic liver disease in a haemodialysis unit
45. Molecular analysis of intraspousal transmission of hepatitis C virus
46. The natural history of community-acquired hepatitis C in the United States
47. Histopathology of hepatitis C virus infection
48. Chronic liver disease in central Harlem: The role of alcohol and viral hepatitis
49. Prognosis of hepatitis C: Results of a large prospective cohort study
50. Hepatitis C virus infection and liver disease: Peculiar epidemiological and clinicopathological features
51. Hepatitis C infection in patients with chronic hepatitis B: Curiosity or co-factor?
52. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection
53. Clinical outcomes after transfusion-associated hepatitis C
54. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis
55. Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection
56. A role for hepatitis C virus infection in type II cryoglobulinemia
57. Autoimmune hepatitis and hepatitis C virus infection
58. Hepatitis C virus associated membranous glomerulonephritis
59. Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association
60. Evidence of a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population
61. Increased prevalence of diabetes mellitus in patients with chronic hepatitis C infection
62. Further evidence for an association between non-insulin dependent diabetes mellitus and chronic hepatitis C virus infection
63. Hepatitis C; diagnostic assays
64. Hepatitis C virus antibodies in chronic active hepatitis: Pathogenetic factor or false-positive result?
65. New kit on the block: Evaluation of second-generation assays for detection of antibody to the hepatitis C virus
66. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection
67. Importance of age in chronic hepatitis C virus infection
68. Persistent hepatitis C viremia predicts late relapse after sustained response to alpha-interferon in chronic hepatitis C
69. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha-interferon
70. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C with alpha-interferon
71. Randomised trial of interferon alfa2b plus ribavirin versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
72. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
73. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
74. Interferon alpha therapy for hepatitis C virus infection after liver transplantation
75. Long-term outcome of hepatitis C infection after liver transplantation
76. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C
77. Therapy of chronic hepatitis C after liver transplantation: Multicenter Italian experience
78. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees
79. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses
80. Lack of protective immunity against reinfection with hepatitis C virus
81. T-Lymphocyte response to hepatitis C virus in different clinical courses of infection
82. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection
83. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile
84. Evidence that hepatitis D virus needs hepatitis B virus to cause hepatocellular damage
85. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen: An active and progressive disease unresponsive to immunosuppressive treatment
86. Diagnosis of hepatitis delta virus infection
87. Treatment of chronic hepatitis D with interferon alfa-2a
88. Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis
89. Ribavirin for chronic hepatitis D: A pilot study
90. Lamivudine for chronic delta hepatitis
91. Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissable agent
92. Effect of hepatitis G virus infection on chronic hepatitis C
93. Histopathologic impact of GB virus C infection on chronic hepatitis C
94. Influence of GB virus-C/hepatitis G virus infection on the long-term course of chronic hepatitis B
95. Absence of hepatitis G virus within liver tissue of patients undergoing liver transplantation for cryptogenic cirrhosis
96. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology
97. Molecular cloning and characterization of a novel DNA virus (TTV) associated with posttransfusion hepatitis of unknown etiology
98. Infection with an unenveloped DNA virus (TTV) in patients with acute or chronic liver disease of unknown aetiology and in those positive for hepatitis C virus RNA
99. Detection of novel DNA virus (TTV) in blood donors and blood products
100. Presence of a newly described human DNA virus (TTV) in patients with liver disease
101. TT-virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis